cas 10438-96-7|| where to buy Methylsulfamoyl Chloride

Nom du produit:Methylsulfamoyl Chloride

IUPAC Name:N-methylsulfamoyl chloride

Unité d'emballage	Stock disponible	Prix($)
CM386219-5g	in stock	ƴŮǙ
CM386219-10g	in stock	ħƈħ
CM386219-25g	in stock	ŮŌĳ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 10438-96-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:10438-96-7; Formule moléculaire:CH4ClNO2S; Point de fusion:-; Code SMILES:CNS(Cl)(=O)=O; Densité:

: Numéro de catalogue:CM386219; Poids moléculaire:129.56; Point d'ébullition:; N° Mdl:MFCD00126938; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: NST-628; Nested Therapeutics’ lead program, NST-628, is an oral, brain-penetrant pan-RAF-MEK non-degrading molecular glue that lacks paradoxical pathway activation through the prevention of RAF paralog heterodimerization. By inhibiting the phosphorylation and activation of MEK by RAF, NST-628 targets a critical step in the RAS/RAF/MAPK signaling pathway. Preclinically, NST-628 results in broad efficacy, high tolerability, CNS activity across various RAS- and RAF-driven tumor models, and has the potential to deliver transformative clinical benefits both as a monotherapy and as a key component in combination therapies. Now, NST-628 has advanced to a Ph. I trial in patients with refractory MAPK pathway mutated/dependent advanced solid tumors.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.